APA warns psychiatrists against diagnosing public figures from afar

When public figures act or speak differently than usual—or differently than anyone else around them—some people (and the media that cater to them) look for medical or mental-health related explanations. But the American Psychiatric Association (APA) has issued a reminder to its members: Don’t engage in such public analysis diagnostics when you don’t actually know the person in question.

According to NPR, the desire for such speculation has reached new levels this year, especially surrounding Donald Trump.

A statement on the organization’s website said, “The unique atmosphere of this year's election cycle may lead some to want to psychoanalyze the candidates, but to do so would not only be unethical, it would be irresponsible.”

But, NPR reports, some people still want the (responsible) professional opinion of mental health experts when public figures seem to truly get out of hand. Check out NPR to see why some people are saying those opinions could be an important tool for voters, despite the APA’s warnings:

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.